Technology platforms for pharmacogenomic diagnostic assays

Nature Reviews Drug Discovery

Volumn 3, Issue 9, 2004, Pages 749-761

  Koch, Walter H ^a  

^a ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; CYTOCHROME P450 2D6; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; FLUOROURACIL; GEFITINIB; MONOCLONAL ANTIBODY; NEUROLEPTIC AGENT; PHYCOERYTHRIN; PROTEIN TYROSINE KINASE INHIBITOR; STREPTAVIDIN; TRASTUZUMAB;

BREAST CANCER; CARDIOVASCULAR DISEASE; DIAGNOSTIC KIT; DRUG METABOLISM; DRUG RESPONSE; DRUG TOXICITY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG CANCER; MENTAL DISEASE; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; PROBABILITY; PSEUDOGENE; REVIEW; RISK ASSESSMENT; TECHNOLOGY;

ANIMALS; DIAGNOSIS; GENETIC MARKERS; GENOTYPE; HUMANS; MEDICAL ONCOLOGY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, PROTEIN;

EID: 4544367874     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1496     Document Type: Review

References (83)

1. Weinshilboum, R. Inheritance and drug response. N. Engl. J. Med. 348, 529-537 (2003).
2. Evans, W. E. & Relling, M. V. Moving towards individualized medicine with pharmacogenomics. Nature 429, 464-468 (2004).
3. Ingelman-Sundberg, M., Oscarson, M. & McLellan, R. A. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci. 20, 342-349 (1999).
4. Goldstein, J. A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52, 349-355 (2001).
5. Desta, Z., Zhao, X., Shin, J. G. & Flockhart, D. A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41, 913-958 (2002).
6. Levy, G. N. & Weber W.W. in Interindividual Variability in Human Drug Metabolism (ed. Pacifici, G. M. & Pelkonen, O.) 333-357 (Taylor and Francis, London and New York, 2001).
7. Weinshilboum, R. M., Otterness, D. M. & Szumlanski, C. L. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu. Rev. Pharmacol. Toxicol. 39, 19-52 (1999).
8. Townsend, D. & Tew, K. Cancer drugs, genetic variation and the glutathione-S-transferase gene family. Am. J. Pharmacogenomics 3, 157-172 (2003).
9. Cascorbi, I. Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. Eur. J. Clin. Invest. 33 (Suppl. 2), 17-22 (2003).
10. Dracopoli, N. C. Pharmacogenomic applications in clinical drug development. Cancer Chemother. Pharmacol. 52 (Suppl 1), S57-S60 (2003).
11. Ross, J. S. et. al. Pharmacogenomics. Adv. Anat. Pathol. 11, 211-220 (2004).
12. Holleman, A. et. al. Gene-expression patterns in drug resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med. 351, 533-542 (2004).
13. Newton, C. R. et. al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 17, 2503-2516 (1989).
14. Holland, P. M., Abramson, R. D., Watson, R. & Gelfand, D. H. Detection of specific polymerase chain reaction product by utilizing the 5′ - 3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc. Natl Acad. Sci. USA 88, 7276-7280 (1991).
15. Lyamichev, V. et. al. Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nature Biotechnol. 17, 292-296 (1999).
16. Syvanen, A. C., Aalto-Setala, K., Harju, L., Kontula, K. & Soderlund, H. A primer-guided nucleotide incorporation assay in the genotyping of apolipoprotein E. Genomics 8, 684-692 (1990).
17. Barany, F. Genetic disease detection and DNA amplification using cloned thermostable ligase. Proc. Natl Acad. Sci. USA 1, 189-193 (1991).
18. Fan, J. B. et. al. Parallel genotyping of human SNPs using generic high-density oligonucleotide tag arrays. Genome Res. 10, 853-860 (2000).
19. Haff, L. A. & Smirnov, I. P. Single-nucleotide polymorphism identification assays using a thermostable DNA polymerase and delayed extraction MALDI-TOF mass spectrometry. Genome Res. 7, 378-388 (1997).
20. Bugawan, T. L., Apple, R. & Erlich, H. A. A method for typing polymorphism at the HLA-A locus using PCR amplification and immobilized oligonucleotide probes. Tissue Antigens 44, 137-147 (1994).
21. Cronin, M. T. et al. Cystic fibrosis mutation detection by hybridization to light-generated DNA probe arrays. Hum Mutat. 7, 244-255 (1996).
22. Armstrong, B., Stewart, M. & Mazumder, A. Suspension arrays for high throughput, multiplexed single nucleotide polymorphism genotyping. Cytometry 40, 102-108 (2000).
23. Murphy, G. M. Jr et al. CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology 25, 737-743 (2001).
24. Chou, W. H. et. al. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem. 49, 542-551 (2003).
25. Schena, M. et al. Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc. Natl Acad. Sci. USA 93, 10614-10619 (1996).
26. DeRisi, J. et. al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nature Genet. 14, 457-460 (1996).
27. Scherf, U. et. al. A gene expression database for the molecular pharmacology of cancer. Nature Genet. 24, 236-244 (2000).
28. Liotta L. & Petricoin, E. Molecular profiling of human cancer. Nature Rev. Genet. 1, 48-56 (2000).
29. Goldstein, J. A. & Blaisdell, J. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol. 272, 210-218 (1996).
30. Claassen, J. D., Pascoe, N., Schatzberg, A. F. & Murphy, G. M. Jr. Rapid detection of the C-1496G polymorphism in the CYP2D62 allele. Clin. Chem. 47, 2153-2155 (2001).
31. Higuchi, R., Dollinger, G., Walsh, P. S. & Griffith, R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology NY 10, 413-417 (1992).
32. Schneeberger, C., Speiser, P., Kury, F. & Zeillinger, R. Quantitative detection of reverse transcriptase-PCR products by means of a novel and sensitive DNA stain. PCR Methods Appl. 4, 234-238 (1995).
33. Livak, K. J. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal. 14, 143-149 (1999).
34. Aithal, G. P., Day, C. P., Kesteven, P. J. & Daly, A. K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and disk of bleeding complications. Lancet 353, 717-719 (1999).
35. Teupser, D., Rupprecht, W., Lohse, F. & Thiery, J. Fluorescence-based detection of the CETP TaqIB polymorphism: false positives with the TaqMan-based exonuclease assay attributable to a previously unknown gene variant. Clin Chem. 47, 852-857 (2001).
36. Lay, M. J. & Wittwer, C. T. Real-time fluorescence genotyping of factor V Leiden during rapid-cycle PCR. Clin Chem. 43, 2262-2267 (1997).
37. Bernard, P. S., Ajioka, R. S., Kushner, J. P. & Wittwer, C. T. Homogeneous multiplex genotyping of hemochromatosis mutations with fluorescent hybridization probes. Am. J. Pathol. 153, 1055-1061 (1998).
38. Burian, M., Grosch, S., Tegeder, I. & Geisslinger, G. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br. J. Clin. Pharmacol. 54, 518-521 (2002).
39. Wikman, H. et al. Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. Pharmacogenetics 11, 157-168 (2001).
40. Wusk, B. et al. Thiopurine S-methyltransferase polymorphisms: efficient screening method for patients considering taking thiopurine drugs. Eur. J. Clin. Pharmacol. 60, 5-10 (2004).
41. Warshawsky, I. et al. Detection of a novel point mutation of the prothrombin gene at position 20209. Diagn. Mol. Pathol. 11, 152-156 (2002).
42. Tag, C. G., Gressner, A. M. & Weiskirchen, R. An unusual melting curve profile in LightCycler multiplex genotyping of the hemochromatosis H63D/C282Y gene mutations. Clin. Biochem. 34, 511-515 (2001).
43. Emanuel, P. A. et al. Detection of Francisella tularensis within infected mouse tissues by using a hand-held PCR thermocycler. J. Clin. Microbiol. 41, 689-693 (2003).
44. Kwiatkowski, R. W., Lyamichev, V., de Arruda, M. & Neri, B. Clinical, genetic, and pharmacogenetic applications of the Invader assay. Mol. Diagn. 4, 353-364 (1999).
45. de Arruda, M, et al. Invader technology for DNA and RNA analysis: principles and applications. Expert Rev. Mol. Diagn. 2, 487-496 (2002).
46. Neville, M, et al. Characterization of cytochrome P450 2D6 alleles using the Invader system. Biotechniques. 34 (Suppl.), 40-43 (2002).
47. Saiki, R. K., Bugawan, T. L., Horn, G. T., Mullis, K. B. & Erlich, H. A. Analysis of enzymatically amplified β-globin and HLA-DQα DNA with allele-specific oligonucleotide probes. Nature 324, 163-166 (1986).
48. Ye, F. et al. Fluorescent microsphere-based readout technology for multiplexed human single nucleotide polymorphism analysis and bacterial identification. Hum. Mutat. 17, 305-316 (2001).
49. Gilles, P. N., Wu, D. J., Foster, C. B., Dillon, P. J. & Chanock, S. J. Single nucleotide polymorphic discrimination by an electronic dot blot assay on semiconductor microchips. Nature Biotechnol. 17, 365-370 (1999).
50. Lipshutz, R. J., Fodor, S. P., Gingeras, T. R. & Lockhart, D. J. High density synthetic oligonucleotide arrays. Nature Genet. 21 (Suppl. 1), 20-24 (1999).
51. Taylor, J. D. et al. Flow cytometric platform for high-throughput single nucleotide polymorphism analysis. Biotechniques 30, 661-666, 668-669 (2001).
52. Matsuzai, H. et al. Parallel genotyping of over 10,000 SNPs using a one-primer assay on a high-density oligonucleotide array. Genome Res. 14, 414-425 (2004).
53. Kennedy, G. C. et al. Large-scale genotyping of complex DNA. Nature Biotechnol. 21, 1233-1237 (2003).
54. Patil, N. et al. Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science 294, 1719-1723 (2001).
55. Koch, W. H. in Clinical Pharmacogenomics (ads Wong, S. H., Linder, M. W. & Valdes, R.) (in the press).
56. Sebastian, J. & Faruki, H. Update on HIV resistance and resistance testing. Med. Res. Rev. 24, 115-125 (2004).
57. Soussi, T. & Beroud, C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nature Rev. Cancer 1, 233-240 (2001).
58. Woods, Y. L. & Lane, D. P. Exploiting the p53 pathway for cancer diagnosis and therapy. Hematol. J. 4, 233-247 (2003).
59. Petersen, S., Thames, H. D., Nieder, C., Petersen, C. & Baumann, M. The results of colorectal cancer treatment by p53 status: treatment-specific overview. Dis. Colon Rectum 44, 322-333 (2001).
60. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
61. Yager, T. D. et al. High performance DNA sequencing, and the detection of mutations and polymorphisms, on the Clipper sequencer. Electrophoresis 20, 1280-1300 (1999).
62. Bharaj, B. S., Angelopoulou, K. & Diamandis, E. P. Rapid sequencing of the p53 gene with a new automated DNA sequencer. Clin. Chem. 44, 1397-1403 (1998).
63. Kozel, M. J. et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nature Med. 2, 753-759 (1996).
64. Takahashi, Y. et al. Clinical application of oligonucleotide probe array for full-length gene sequencing of TP53 in colon cancer. Oncology 64, 54-60 (2003).
65. Wen, W. H. et al. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. Cancer Res. 60, 2716-2722 (2000).
66. The Tumor Analysis Best Practices Working Group. Expression Profiling - best practices for data generation and interpretation in clinical trials. Nature Rev. Genet. 5, 229-237 (2004).
67. Parmigiani, G., Garrett, E., Irizarry, R. & Zeger, S. in The Analysis of Gene Expression Data, (ads Parmigiani, G., Garrett, E., Irizarry, R. & Zeger, S.) 1-45 (Springer, New York, 2003).
68. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl J. Med. 350, 2129-2139 (2004).
69. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
70. Ross, M. E. et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 102, 2951-2959 (2003).
71. Haferlach, T. et al. Gene expression profiling as a tool for the diagnosis of acute leukemias. Semin. Hematol. 40, 281-295 (2003).
72. Boyer, J., Maxwell, P. J., Longley, D. B. & Johnston, P. G. 5-Fluorouracil: identification of novel downstream mediators of tumor response. Anticancer Res. 24, 417-423 (2004).
73. Chang, J. C. et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362-369 (2003).
74. Ma, X. J. et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5, 607-616 (2004).
75. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research & Center for Devices and Radiological Health. 'Draft' Guidance for Industry: Pharmacogenomics Data Submissions. (November, 2003).
76. Bradford, L. D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3, 229-243 (2002).
77. Kimura, S., Umeno, M., Skoda, R. C., Meyer, U. A. & Gonzalez, F. J. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am. J. Hum. Genet. 45, 889-904 (1989).
78. Heim, M. H. & Meyer, U. A. Evolution of a highly polymorphic human cyochrome P450 gene cluster: CYP2D6. Genomics 14, 49-58 (1992).
79. Ingelman-Sundberg, M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci. 25, 193-200 (2004)
80. Sachse, C., Brockmoller, J., Bauer, S. & Roots, I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60, 284-295 (1997).
81. Steen, V. M. et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 5, 215-223 (1995).
82. Lovlie, R., Daly, A. K., Molven, A., Idle, J. R. & Steen, V. M. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 392, 30-34 (1996).
83. Ahrendt, S. A. et al. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc. Natl Acad. Sci. USA 96, 7382-7387 (1999).